SG11201608035UA - Compositions and methods related to diagnosis of prostate cancer - Google Patents

Compositions and methods related to diagnosis of prostate cancer

Info

Publication number
SG11201608035UA
SG11201608035UA SG11201608035UA SG11201608035UA SG11201608035UA SG 11201608035U A SG11201608035U A SG 11201608035UA SG 11201608035U A SG11201608035U A SG 11201608035UA SG 11201608035U A SG11201608035U A SG 11201608035UA SG 11201608035U A SG11201608035U A SG 11201608035UA
Authority
SG
Singapore
Prior art keywords
diagnosis
compositions
prostate cancer
methods related
methods
Prior art date
Application number
SG11201608035UA
Inventor
David Steinmiller
Vincent Linder
Kim Pettersson
Timo Lovgren
Hans Lilja
Peter T Scardino
Andrew J Vickers
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of SG11201608035UA publication Critical patent/SG11201608035UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
SG11201608035UA 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer SG11201608035UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
SG11201608035UA true SG11201608035UA (en) 2016-10-28

Family

ID=54196462

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808585TA SG10201808585TA (en) 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer
SG11201608035UA SG11201608035UA (en) 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201808585TA SG10201808585TA (en) 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer

Country Status (24)

Country Link
US (2) US11761962B2 (en)
EP (2) EP3299977A1 (en)
JP (3) JP6775488B2 (en)
KR (1) KR102505543B1 (en)
CN (2) CN114740202A (en)
AR (1) AR099883A1 (en)
AU (1) AU2015237270B2 (en)
BR (1) BR112016022407A2 (en)
CA (1) CA2944001C (en)
CL (1) CL2016002419A1 (en)
DE (1) DE202015009668U1 (en)
DK (1) DK3123381T3 (en)
EA (1) EA201691952A1 (en)
ES (1) ES2964706T3 (en)
FI (1) FI3123381T3 (en)
IL (2) IL247981B (en)
MX (2) MX2016012667A (en)
MY (1) MY192513A (en)
PE (1) PE20170298A1 (en)
PL (1) PL3123381T3 (en)
PT (1) PT3123381T (en)
SG (2) SG10201808585TA (en)
TW (1) TWI687688B (en)
WO (1) WO2015148979A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202492B2 (en) 2007-05-04 2012-06-19 Opko Diagnostics, Llc Fluidic connectors and microfluidic systems
DE202010018623U1 (en) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Structures for controlling the light interaction with microfluidic devices
MY171654A (en) 2012-03-05 2019-10-22 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
HUE055020T2 (en) 2015-03-27 2021-11-29 Opko Diagnostics Llc Prostate antigen standards and uses thereof
PL3359189T3 (en) * 2015-10-05 2021-12-20 Fredax Ab Humanized anti psa (5a10) antibodies
AU2016365824B2 (en) 2015-12-11 2022-07-21 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
CN108430639B (en) 2015-12-29 2021-03-23 欧普科诊断有限责任公司 Fluid collection device and related methods
EP3566233A1 (en) * 2017-01-08 2019-11-13 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (en) 2018-04-18 2019-12-05 (주)유로테크 Biomarkers for diagnosis of prostate cancer and uses thereof
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
KR20240022906A (en) * 2022-08-12 2024-02-20 (주)맥시온 Multiple Biomarkers for Cancer Diagnosis and Uses Thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (en) 1990-07-23 1990-07-23 Hans Lilja ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
KR960705501A (en) 1993-10-28 1996-11-08 윌리암 모피트 FLUID SAMPLE COLLECTION AND INTRODUCTION DEVICE
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
EP0843817A1 (en) 1995-08-03 1998-05-27 Akzo Nobel N.V. Diagnostic device
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (en) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Assay procedure with addition in two or more positions
FI980488A (en) 1998-03-04 1999-09-05 Arctic Partners Oy Ab New diagnostic method
FR2780791B1 (en) 1998-07-03 2000-09-01 Bio Merieux METHOD OF SCREENING OR DIAGNOSIS OF ADENOCARCINOMA OR BENIGN PROSTATE PATHOLOGY AND PROCESS FOR IMPLEMENTATION
JP4495349B2 (en) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド Nucleic acid sequences for detecting cancer genetic markers in biological samples
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (en) * 2000-09-27 2000-09-27 Artic Partners Oy Ab A new antibody, immunoassay, and method for detecting prostate cancer
EP1328342A4 (en) 2000-10-10 2006-03-15 Aviva Biosciences Corp An integrated biochip system for sample preparation and analysis
ATE362107T1 (en) 2000-11-20 2007-06-15 Eastern Virginia Med School METHOD AND DEVICE FOR THE QUANTITATIVE DETECTION OF A PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND OTHER PROSTATE MARKERS
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003048736A2 (en) 2001-12-05 2003-06-12 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003242389A1 (en) 2002-05-28 2003-12-12 Jokoh Co., Ltd Immunological chromatograph method test slip reading/quantitative determination device
CN103969449B (en) 2002-08-06 2016-11-23 约翰霍普金斯大学 For detecting the purposes of the biomarker of ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
JP4824540B2 (en) 2003-02-07 2011-11-30 ダイアノキュアー インク． How to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
WO2005056186A1 (en) 2003-12-10 2005-06-23 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
CA2834041C (en) 2003-12-31 2017-05-16 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
CN1953802B (en) 2004-01-26 2011-10-19 哈佛大学 Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
JP2008508538A (en) 2004-08-02 2008-03-21 チルドレンズ・メディカル・センター・コーポレイション Platelet biomarkers for cancer
CA2580494A1 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
BRPI0709176A2 (en) 2006-03-24 2011-06-28 Phenomenome Discoveries Inc Useful biomarkers to diagnose prostate cancer and its methods
WO2008003656A2 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (en) 2006-12-08 2007-06-06 南京大学 Method of predicting serious complication risk degree after gastric cancer operation
JP5523108B2 (en) 2006-12-22 2014-06-18 ファディア・アクチボラグ Prostate kallikrein as a novel allergen
US8202492B2 (en) 2007-05-04 2012-06-19 Opko Diagnostics, Llc Fluidic connectors and microfluidic systems
CA2686954A1 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (en) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 New generation early diagnosis prostate gland cancer reagent kit and preparation method and detection process thereof
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (en) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 Free prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof
US20110039284A1 (en) 2007-10-22 2011-02-17 Samuel Norbert Breit Methods of prognosis
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (en) 2008-02-18 2012-09-19 富士フイルム株式会社 Suction syringe and endoscope suction syringe
EP2281201B1 (en) 2008-05-14 2018-03-28 ETH Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (en) 2008-08-01 2011-11-18 Commissariat Energie Atomique PREDICTION METHOD FOR THE PROGNOSIS OR DIAGNOSIS OR THERAPEUTIC RESPONSE OF A DISEASE AND IN PARTICULAR PROSTATE CANCER AND DEVICE FOR PERFORMING THE METHOD.
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
DK2376226T3 (en) 2008-12-18 2018-10-15 Opko Diagnostics Llc IMPROVED REAGENT STORAGE IN MICROFLUIDIC SYSTEMS AND RELATED ARTICLES AND PROCEDURES
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
DE202010018623U1 (en) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Structures for controlling the light interaction with microfluidic devices
JP2010243406A (en) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Method for detecting extent of clinical condition of liver cancer and chronic liver disease, using discriminant function taking measurement values of afp and pivka-ii as characteristic values
SG175832A1 (en) 2009-05-01 2011-12-29 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US20120122243A1 (en) * 2009-06-04 2012-05-17 Charite Universitatsmedizin Berlin Means and method and means for diagnosing prostate carcinomas
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (en) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 Biomarker indicative of prostate cancer and diagnosis using the same
KR20120138241A (en) * 2010-03-11 2012-12-24 화이자 인코포레이티드 Antibodies with ph dependent antigen binding
CN102939160B (en) 2010-04-16 2016-10-12 欧普科诊断有限责任公司 System and device for sample analysis
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (en) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill immunomodulatory agent and combinations thereof, their use and immunotherapeutic method for real time recontextualization, reprogramming and rebuilding of the immune system
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
US9638706B2 (en) 2011-07-21 2017-05-02 Wako Pure Chemical Industries, Ltd. Standard solution for use in analysis of amino acid in plasma
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
MY171654A (en) 2012-03-05 2019-10-22 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
JP2015524052A (en) * 2012-05-16 2015-08-20 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ How to present the presence or absence of prostate cancer
BR112014032728A2 (en) 2012-06-27 2017-11-28 Berg Llc use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (en) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 Detection kit for prostate specific antigen and preparation method thereof
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
AU2013349721B2 (en) 2012-11-20 2019-03-28 Phadia Ab Prognostic method for individuals with prostate cancer
AU2013349801B2 (en) 2012-11-20 2019-03-07 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
AU2014351611B2 (en) 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
EP4220170A3 (en) 2014-03-11 2023-12-13 Phadia AB Method for detecting a solid tumor cancer
US20170089904A1 (en) 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3268978A1 (en) 2015-03-12 2018-01-17 Thermo Finnigan LLC Methods for data-dependent mass spectrometry of mixed biomolecular analytes
HUE055020T2 (en) 2015-03-27 2021-11-29 Opko Diagnostics Llc Prostate antigen standards and uses thereof
PE20180930A1 (en) 2015-04-29 2018-06-08 Opko Diagnostics Llc COMPOSITIONS AND METHODS FOR ACTIVE SURVEILLANCE FOR PROSTATE CANCER
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
EP3794354A4 (en) 2018-05-16 2022-01-12 Opko Diagnostics, LLC Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
SG10201808585TA (en) 2018-11-29
EP3123381A4 (en) 2018-02-21
IL247981B (en) 2021-02-28
FI3123381T3 (en) 2023-11-27
CA2944001A1 (en) 2015-10-01
JP2017515127A (en) 2017-06-08
IL247981A0 (en) 2016-11-30
KR20170008729A (en) 2017-01-24
IL280039B (en) 2021-12-01
AR099883A1 (en) 2016-08-24
MX2016012667A (en) 2017-01-09
CN114740202A (en) 2022-07-12
WO2015148979A1 (en) 2015-10-01
AU2015237270A1 (en) 2016-10-20
TWI687688B (en) 2020-03-11
BR112016022407A2 (en) 2017-12-12
PT3123381T (en) 2023-12-22
CN106663149A (en) 2017-05-10
US20160025732A1 (en) 2016-01-28
CA2944001C (en) 2023-08-15
MY192513A (en) 2022-08-24
EP3299977A1 (en) 2018-03-28
TW201621320A (en) 2016-06-16
KR102505543B1 (en) 2023-03-02
JP7256781B2 (en) 2023-04-12
PE20170298A1 (en) 2017-04-18
DK3123381T3 (en) 2023-11-27
PL3123381T3 (en) 2024-02-26
ES2964706T3 (en) 2024-04-09
WO2015148979A8 (en) 2016-01-07
JP6775488B2 (en) 2020-10-28
US11761962B2 (en) 2023-09-19
EP3123381B1 (en) 2023-10-11
CL2016002419A1 (en) 2017-03-31
EA201691952A1 (en) 2017-05-31
AU2015237270B2 (en) 2021-09-09
JP2021009157A (en) 2021-01-28
IL280039A (en) 2021-03-01
MX2022002365A (en) 2022-04-06
JP2023017841A (en) 2023-02-07
EP3123381A1 (en) 2017-02-01
DE202015009668U1 (en) 2019-01-21
US20230393137A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
IL280039B (en) Compositions and methods related to diagnosis of prostate cancer
IL273090B (en) Methods and compositions for the treatment of cancer
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
HK1247931A1 (en) Compositions and methods for diagnosis and treatment of cancer
HK1211963A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
SG11201607795UA (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
ZA201701909B (en) Trichoderma compositions and methods of use
SG11201701076TA (en) Diagnosis of cancer
EP2958591A4 (en) Methods and compositions relating to the treatment of cancer
HK1243404A1 (en) Tryptamide compositions and methods of use
HK1213740A1 (en) Methods of making cancer compositions
ZA201506392B (en) Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
GB201407837D0 (en) Methods of cancer therapy
TH1501005132A (en) Composition and methods for diagnosis and treatment of liver cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
ZA201403006B (en) Composition for use in treatment of cancer
GB201405449D0 (en) Treatment of cancer